 FRIENDSWOOD, Texas--BUSINESS WIRE--- CSTL Melanoma--Castle Biosciences, Inc. Nasdaq: CSTL, a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outcomes data in cutaneous melanoma as impacted by DecisionDx-Melanoma. DecisionDx-Melanoma is Castles gene expression profile test that uses an individual patients tumor biology to predict risk of cutaneous melanoma metastasis or 